Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro

Che Chuan Yang; Shieh-Yueh Yang; Jen Jie Chieh; Herng-Er Horng; Chin Yih Hong; Hong-Chang Yang; K. H. Chen; B. Y. Shih; Ta Fu Chen; Ming Jang Chiu

doi:10.1021/cn200028j

Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro

Che Chuan Yang, Shieh-Yueh Yang, Jen Jie Chieh, Herng-Er Horng^*, Chin Yih Hong, Hong-Chang Yang, K. H. Chen, B. Y. Shih, Ta Fu Chen, Ming Jang Chiu

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

88 Citations (Scopus)

Abstract

Magnetic nanoparticles biofunctionalized with antibodies against β-amyloid-40 (Aβ-40) and Aβ-42, which are promising biomarkers related to Alzheimer's disease (AD), were synthesized. We characterized the size distribution, saturated magnetizations, and stability of the magnetic nanoparticles conjugated with anti-Aβ antibody. In combination with immunomagnetic reduction technology, it is demonstrated such biofunctionalized magnetic nanoparticles are able to label Aβs specifically. The ultralow-detection limits of assaying Aβs in vitro using the magnetic nanoparticles via immunomagnetic reduction are determined to a concentration of ~10 ppt (10 pg/mL). Further, immunomagnetic reduction signals of Aβ-40 and Aβ-42 in human plasma from normal samples and AD patients were analyzed, and the results showed a significant difference between these two groups. These results show the feasibility of using magnetic nanoparticles with Aβs as reagents for assaying low-concentration Aβs through immunomagnetic reduction, and also provide a promising new method for early diagnosis of Alzheimer's disease from human blood plasma.

Original language	English
Pages (from-to)	500-505
Number of pages	6
Journal	ACS Chemical Neuroscience
Volume	2
Issue number	9
DOIs	https://doi.org/10.1021/cn200028j
Publication status	Published - 2011 May 30

Keywords

Immunomagnetic reduction
Magnetic nanoparticles
β-amyloid

ASJC Scopus subject areas

Biochemistry
Physiology
Cognitive Neuroscience
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1021/cn200028j

Cite this

@article{c09baf7023084148be956cdab6692d15,

title = "Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro",

abstract = "Magnetic nanoparticles biofunctionalized with antibodies against β-amyloid-40 (Aβ-40) and Aβ-42, which are promising biomarkers related to Alzheimer's disease (AD), were synthesized. We characterized the size distribution, saturated magnetizations, and stability of the magnetic nanoparticles conjugated with anti-Aβ antibody. In combination with immunomagnetic reduction technology, it is demonstrated such biofunctionalized magnetic nanoparticles are able to label Aβs specifically. The ultralow-detection limits of assaying Aβs in vitro using the magnetic nanoparticles via immunomagnetic reduction are determined to a concentration of ~10 ppt (10 pg/mL). Further, immunomagnetic reduction signals of Aβ-40 and Aβ-42 in human plasma from normal samples and AD patients were analyzed, and the results showed a significant difference between these two groups. These results show the feasibility of using magnetic nanoparticles with Aβs as reagents for assaying low-concentration Aβs through immunomagnetic reduction, and also provide a promising new method for early diagnosis of Alzheimer's disease from human blood plasma.",

keywords = "Immunomagnetic reduction, Magnetic nanoparticles, β-amyloid",

author = "Yang, {Che Chuan} and Shieh-Yueh Yang and Chieh, {Jen Jie} and Herng-Er Horng and Hong, {Chin Yih} and Hong-Chang Yang and Chen, {K. H.} and Shih, {B. Y.} and Chen, {Ta Fu} and Chiu, {Ming Jang}",

note = "Publisher Copyright: {\textcopyright} 2011 American Chemical Society.",

year = "2011",

month = may,

day = "30",

doi = "10.1021/cn200028j",

language = "English",

volume = "2",

pages = "500--505",

journal = "ACS Chemical Neuroscience",

issn = "1948-7193",

publisher = "American Chemical Society",

number = "9",

}

TY - JOUR

T1 - Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro

AU - Yang, Che Chuan

AU - Yang, Shieh-Yueh

AU - Chieh, Jen Jie

AU - Horng, Herng-Er

AU - Hong, Chin Yih

AU - Yang, Hong-Chang

AU - Chen, K. H.

AU - Shih, B. Y.

AU - Chen, Ta Fu

AU - Chiu, Ming Jang

PY - 2011/5/30

Y1 - 2011/5/30

N2 - Magnetic nanoparticles biofunctionalized with antibodies against β-amyloid-40 (Aβ-40) and Aβ-42, which are promising biomarkers related to Alzheimer's disease (AD), were synthesized. We characterized the size distribution, saturated magnetizations, and stability of the magnetic nanoparticles conjugated with anti-Aβ antibody. In combination with immunomagnetic reduction technology, it is demonstrated such biofunctionalized magnetic nanoparticles are able to label Aβs specifically. The ultralow-detection limits of assaying Aβs in vitro using the magnetic nanoparticles via immunomagnetic reduction are determined to a concentration of ~10 ppt (10 pg/mL). Further, immunomagnetic reduction signals of Aβ-40 and Aβ-42 in human plasma from normal samples and AD patients were analyzed, and the results showed a significant difference between these two groups. These results show the feasibility of using magnetic nanoparticles with Aβs as reagents for assaying low-concentration Aβs through immunomagnetic reduction, and also provide a promising new method for early diagnosis of Alzheimer's disease from human blood plasma.

AB - Magnetic nanoparticles biofunctionalized with antibodies against β-amyloid-40 (Aβ-40) and Aβ-42, which are promising biomarkers related to Alzheimer's disease (AD), were synthesized. We characterized the size distribution, saturated magnetizations, and stability of the magnetic nanoparticles conjugated with anti-Aβ antibody. In combination with immunomagnetic reduction technology, it is demonstrated such biofunctionalized magnetic nanoparticles are able to label Aβs specifically. The ultralow-detection limits of assaying Aβs in vitro using the magnetic nanoparticles via immunomagnetic reduction are determined to a concentration of ~10 ppt (10 pg/mL). Further, immunomagnetic reduction signals of Aβ-40 and Aβ-42 in human plasma from normal samples and AD patients were analyzed, and the results showed a significant difference between these two groups. These results show the feasibility of using magnetic nanoparticles with Aβs as reagents for assaying low-concentration Aβs through immunomagnetic reduction, and also provide a promising new method for early diagnosis of Alzheimer's disease from human blood plasma.

KW - Immunomagnetic reduction

KW - Magnetic nanoparticles

KW - β-amyloid

UR - http://www.scopus.com/inward/record.url?scp=84865491507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865491507&partnerID=8YFLogxK

U2 - 10.1021/cn200028j

DO - 10.1021/cn200028j

M3 - Article

C2 - 22860173

AN - SCOPUS:84865491507

VL - 2

SP - 500

EP - 505

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 9

ER -

Biofunctionalized magnetic nanoparticles for specifically detecting biomarkers of Alzheimer's disease in vitro

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this